

## LISTING OF THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-40. (Canceled)

41. (Previously presented) A method for increasing adiponectin production in a warm-blooded animal, comprising administering to a warm-blooded animal in need of such treatment an effective amount of one or more HMG-CoA reductase inhibitor(s).

42. (Canceled)

43. (Previously presented) The method according to claim 41, wherein the HMG-CoA reductase inhibitor is selected from the group consisting of pravastatin, lovastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, pitavastatin and rosuvastatin.

44. (Previously presented) The method according to claim 41, wherein the HMG-CoA reductase inhibitor is a water-soluble HMG-CoA reductase inhibitor.

45. (Previously presented) The method according to claim 41, wherein the HMG-CoA reductase inhibitor is selected from the group consisting of pravastatin or a derivative thereof and rosuvastatin or a derivative thereof.

46. (Previously presented) The method according to claim 41, wherein the HMG-CoA reductase inhibitor is selected from the group consisting of pravastatin and rosuvastatin.

LAW OFFICES OF  
CHRISTENSEN O'CONNOR JOHNSON KINDNESS<sup>PLLC</sup>  
1420 Fifth Avenue  
Suite 2800  
Seattle, Washington 98101  
206.682.8100

47. (Previously presented) The method according to claim 41, wherein the HMG-CoA reductase inhibitor is pravastatin.

48. (Previously presented) A method for treatment of hypoadiponectinemia in a warm-blooded animal, comprising administering to a warm-blooded animal in need of such treatment an effective amount of one or more water-soluble HMG-CoA reductase inhibitor(s).

49-54. (Canceled)

55. (Previously presented) The method according to claim 48, wherein the water-soluble HMG-CoA reductase inhibitor is selected from the group consisting of pravastatin and rosuvastatin.

56. (Previously presented) The method according to claim 48, wherein the water-soluble HMG-CoA reductase inhibitor is pravastatin.

57. (Previously presented) The method according to any one of claims 41 and 48, wherein the warm-blooded animal is a human.

58. (Canceled)

59. (Previously presented) The method according to claim 41, wherein the HMG-CoA reductase inhibitor is selected from the group consisting of pravastatin and rosuvastatin, and wherein the warm-blooded animal is a human.

60. (Previously presented)) The method according to claim 41, wherein the HMG-CoA reductase inhibitor is pravastatin, and wherein the warm-blooded animal is a human.

LAW OFFICES OF  
CHRISTENSEN O'CONNOR JOHNSON KINDNESS<sup>PLC</sup>  
1420 Fifth Avenue  
Suite 2800  
Seattle, Washington 98101  
206.682.8100

61. (Previously presented) The method according to claim 48, wherein the water-soluble HMG-CoA reductase inhibitor is selected from the group consisting of pravastatin and rosuvastatin, and wherein the warm-blooded animal is a human.

62. (Previously presented) The method according to claim 48, wherein the water-soluble HMG-CoA reductase inhibitor is pravastatin, and wherein the warm-blooded animal is a human.

LAW OFFICES OF  
CHRISTENSEN O'CONNOR JOHNSON KINDNESS<sup>PLLC</sup>  
1420 Fifth Avenue  
Suite 2800  
Seattle, Washington 98101  
206.682.8100